Entries tagged "Watson Pharmaceuticals Inc."

You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "Watson Pharmaceuticals Inc.."

11 result(s) displayed (1 - 11 of 11)

Actavis acquires Warner Chilcott for $8.5B

Deal represents a 34% premium to Dublin target's share price prior to May 9 disclosure of merger discussions. Continue reading

Posted on May 20, 2013 9:28 AM

FTC eyes Watson, Actavis generic drug portfolios

Watson Pharmaceuticals Inc.'s bid to become the world's third-largest generic drug company through the €4.25 billion ($5.62 billion) acquisition of Switzerland's Actavis Group hf will get extended scrutiny from the U.S. Federal Trade Commission.Parsippany, N.J.-based Watson said Thursday that it... Continue reading

Posted on July 13, 2012 10:30 AM

Warner Chilcott admits takeover talk

Discussions with potential bidders are at a preliminary stage, says the Irish drugmaker, which is 30.6% owned by THL, Bain Capital and CCMP Capital Advisors Continue reading

Posted on April 30, 2012 3:15 PM

Watson to buy Actavis for $5.6B

The pharma company expands its generics business with its largest acquisition so far. Continue reading

Posted on April 26, 2012 11:24 AM

Watson chief hinted at large acquisition

Rumors swirl of a deal for Actavis Group amid solid rationales for a deal. Continue reading

Posted on March 22, 2012 3:50 PM

Columbia Labs to look for M&A cure

The failure to get regulatory approval for its lead product in development and a slumping stock price has led the maker of a drug designed to prevent premature births to assess its strategic options, including a sale. Continue reading

Posted on March 15, 2012 2:23 PM

FDA issues key generic-drug guidelines

The draft outlines the approval process for biosimilars Continue reading

Posted on February 13, 2012 9:16 AM

Watson Pharma chief: more acquisitions

CEO Paul Bisaro says the pharma will seek balance through M&A Continue reading

Posted on January 12, 2012 12:42 PM

Teva ordered to sell rights to three generics

The FTC clearance of the $6.8 billion takeover of Cephalon comes as the EC continues to review the transaction. Continue reading

Posted on October 10, 2011 11:17 AM

Par Pharmaceutical buys rival Anchen

Par Pharmaceutical Cos. said Wednesday, Aug. 24, that it will buy privately held rival Anchen Pharmaceuticals Inc. for $410 million in cash to extend its portfolio of generic products.The deal is part of a rush by generic drug manufacturers to... Continue reading

Posted on August 24, 2011 11:16 AM

Watson sticks with Latham

When Watson Pharmaceuticals Inc. agreed to buy privately held Arrow Group for $1.75 billion, it used a team led by R. Scott Shean and Adel Aslani-Far at Latham & Watkins LLP. Continue reading

Posted on July 6, 2009 11:10 AM

Movable Type search results powered by Fast Search